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Cisplatin (CDDP) is currently one of the most effective FDA-approved treatments for breast cancer. Previous
studies have shown that CDDP-induced cell death in human breast cancer (MCF-7) cells is associated with
disruption of calcium homeostasis. However, whether the sensitivity of breast cancer cells to cisplatin is associ-
ated with dysregulation of the expression of calcium-binding proteins (CaBPs) remains unknown. In this study, we
evaluated the effect of the intracellular calcium chelator (BAPTA-AM) on viability of MCF-7 cells in the presence
of toxic and sub-toxic doses of cisplatin. Furthermore, this study assessed the expression of CaBPs, calmodulin,
S100A8, and S100A14 in MCF-7 cells treated with cisplatin. Cell viability was determined using MTT-based in
vitro toxicity assay. Intracellular calcium imaging was done using Fluo-4 AM, a cell-permeant fluorescent calcium
indicator. Expression of CaBPs was tested using real-time quantitative PCR. Exposure of cells to increasing
amounts of CDDP correlated with increasing fluorescence of the intracellular calcium indicator, Fluo-4 AM.
Conversely, treating cells with cisplatin significantly decreased mRNA levels of calmodulin, S100A8, and
S100A14. Treatment of the cells with calcium chelator, BAPTA-AM, significantly enhanced the cytotoxic effects of
sub-toxic dose of cisplatin. Our results indicated a statistically significant negative correlation between calmod-
ulin, S100A8, and S100A14 expression and sensitivity of breast cancer cells to a sub-toxic dose of cisplatin. We
propose that modulating the activity of calcium-binding proteins, calmodulin, S100A8, and S100A14, could be
used to increase cisplatin efficacy, lowering its treatment dosage while maintaining its chemotherapeutic value.1. Introduction
Cisplatin continues to be among the best drugs used in clinical
oncology. It has been used in the treatment of several tumors in both
children [1,2], and adults [3]. However, cisplatin chemotherapeutic ef-
ficacy has been hampered by two serious limitations: acquisition of
cisplatin resistance in cancer cells [4] and increase in cytotoxicity to vital
organs, leading to adverse effects including nephrotoxicity [5,6] and
ototoxicity [2,7]. Despite the extensive current knowledge on molecular
mechanisms implicated in cisplatin cytotoxicity, there is still active
research to lower its cytotoxicity while maintaining its cancer-specific
therapeutic benefits.
Calcium (Ca2þ) is a key player in cellular signaling controlling
cellular processes resulting in proliferation or cell death [8,9]. At rest,
cells maintain low intracellular calcium [Ca2þ]i through removal of
calcium from cytoplasm via Ca2þ extrusion at the cell membrane and
Ca2þ intake into the endoplasmic reticulum (ER) [10]. In addition,Hodeify).
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and to regulate Ca2þ-mediated cellular processes. Increased [Ca2þ]i is
mediated through several pathways, including Ca2þ release from ER
through inositol 1,4,5 trisphosphate receptor (IP3R) [11], calcium influx
through plasma membrane in response to different signals such as store
depletion, phospholipase C (PLC)-associated receptors, and diac-
ylglycerol signaling [12, 13, 14, 15].
The remodeling of calcium signaling in cancer cells is regulated by
multiple pathways, including Ca2þ reuptake and release at the plasma
membrane and from intracellular stores, store-operated calcium entry,
and regulation effect of CaBPs [16,17]. The differential regulation of
these components depends on the cancer type and tumor stage [18, 19,
20]. The association of [Ca2þ]i with cisplatin-resistance has been
demonstrated by several studies. In cisplatin-resistant lung cancer cells,
[Ca2þ]i level was reduced compared to that of the sensitive parental cell
line [21]. Other studies showed that cisplatin elevates [Ca2þ]i leading to
apoptosis in several tumor cell lines [22,23]. Schr€odl et al [24]5 January 2021
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was correlated with disruption in the expression of IP3R. Xu et al [25]
demonstrated that cisplatin-induced Ca2þ release from the ER led to
mitochondrial calcium overload and promoted apoptosis in
cisplatin-sensitive but not cisplatin-resistant ovarian cancer cells. The
same group reported that cisplatin resistance in these cells is mediated by
decrease oxidative stress associated with failure of calcium regulation
[26]. On the other hand, cisplatin resistance in head and squamous
carcinoma cells was associated with PLC-dependent Ca2þ mobilization
[27].
Calcium-modulating drugs, including calcium chelators, have been
shown to differentially affect cancer cells sensitivity to CDDP [28]. In
breast cancer cells, Al-Taweel et al [29] demonstrated that cisplatin
induced cell death is associated with disruption of calcium homeostasis
and that [Ca2þ]i increase was reduced in resistant MCF-7 cells. Other
studies have reported that several members of the so-called calcium--
binding proteins (CaBPs) that participate in Ca2þ homeostasis and
signaling, are highly expressed in several types of tumors, including
breast cancer [30, 31, 32, 33]. However, the effect of the combination of
calcium signaling modulators on the sensitivity of MCF-7 cells at
sub-toxic and toxic doses of cisplatin, and potential changes in expression
of CaBPs has not been explored. In this study, we evaluated the effect of
intracellular calcium chelator, BAPTA-AM, on the viability of MCF-7 cells
in the presence of toxic and sub-toxic doses of cisplatin. We further aimed
to study the changes in the expression of specific calcium-binding pro-
teins that have been associated with breast tumor progression in
CDDP-treated cells with and without intracellular calcium chelator.
2. Materials and methods
2.1. Materials
Cisplatin (CDDP) was purchased from TCI (Tokyo, Japan). BAPTA-
AM from Abcam (Cambridge, MA, USA), and Fluo-4 AM from Thermo
Fisher Scientific (Waltham, MA, USA). Glass-bottomed culture dishes for
imaging from MatTek (Ashland, MA). Primers were ordered from Gene
Link (NY, USA).2.2. Cell culture and treatments
Human breast cancer (MCF-7) cells were grown at 37 Cwith 5% CO2
in RPMI-1640 medium supplemented with 10% fetal bovine serum and 2
mM L-Glutamine. After split, cells were maintained overnight to reach
60–70% confluency before treatments. Cisplatin was added to cultures,
where indicated, and the cells were grown for an additional 18 h. BAPTA-
AM was dissolved in DMSO and added 30 min before cisplatin to final
concentration of 10 μM.2.3. In vitro toxicity assay
Cell proliferation was determined by 3-[4,5- dimethylthiazol-2-yl]-
2,5 diphenyltetrazolium bromide (MTT) assay (In vitro Toxicology
Assay Kit, MTT based, Sigma M-5655, St. Louis, MO, USA) according to
the manufacturer's protocol. Briefly, 10,000 cells were seeded per well on
96-well plate overnight to allow attachment. After treatment with drugs,
the MTT drug was reconstituted with serum free media and 30 μl was
added to each well. Following incubation at 37 C for 4 h, 300 μl MTT
solubilization solution was added to each well. The plate was incubated
in the dark for ~20 min with occasional mixing to dissolve MTT for-
mazan crystals. Absorbance was measured at 490 nm using Biotek
ELx800 microplate reader (Ontario, Canada). Cell viability percentage
was calculated based on the absorbance ratio between treated and the
untreated control multiplied by 100.2
2.4. Light microscopy and fluorescence microscopy
Cells were photographed with an inverted OPTIKA XDS-2 microscope
(Optika, Italy) with 10X and 20X objective. Fluorescent imaging was
done on cells plated on poly-D-lysine coated glass-bottomed plates
(MatTek Corporation) to reach 50–60% confluency before treated, as
indicated. Intracellular calcium imaging was done using Fluo-4 AM, a
cell-permeant fluorescent calcium indicator (ThermoFischer Scientific,
Waltham, MA, USA). Following treatment, cells were washed in Hanks’
balanced salt solution (HBSS, pH 7.2) and loaded with 5 μM Fluo-4 AM
for 30 min in the dark at 37 C. Cells were washed in HBSS and then
incubated in the same buffer for another 20 min before imaging by
Optika XDS-2 inverted microscope with M-795 fluorescence system
(Optika, Italy) using green/FITC filter.
To visualize nuclei, cells were fixed in 4 % paraformaldehyde (PFA)
for 10 min, washed with PBS, and incubated with DAPI (Sigma Aldrich,
Missouri, USA). Images were taken using 40X objective and were pro-
cessed using Adobe Photoshop CS6.
2.5. Real time-PCR
Total RNA was extracted from MCF-7 cells using the RNeasy Mini kit
(Qiagen, Valencia, CA, USA). cDNA was produced from 1.8 μg of total
RNA by FIREScript RT cDNA Synthesis KIT (Solis BioDyne, Tartu,
Estonia) using random primers following manufacturer's protocol. Real-
time quantitative PCR was performed with 5x HOT FIREPol® Eva-
Green® qPCR Supermix kit (Solis BioDyne, Tartu, Estonia) using Ste-
pOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA).
The cycling protocol was as follows: Initial activation at 95 C for 12 min,
followed by 40 cycles at 95 C for 15 s, annealing at 53 C for 30 s,
elongation at 72 C for 30 s. GAPDH was used as the reference gene, and
fold change in gene expression was calculated making use of the
comparative CT (2ΔΔCT) method. The relative mRNA abundance was
determined by the ratio of the sample to control. Primers for tested genes
were as follows: Calmodulin: forward 50-GGCATTCCGAGTCTTTGACAA-
30 and reverse 50-CCGTCTCCATCAATATCTGCT-30, S100A8: forward 50-
GGGATGACCTGAAGAAATTGCTA-30 and reverse 50-TGTTGA-
TATCCAACTCTTTGAACCA-30, S100A14: 50-GTCGGTCAGCCAACGCA-
GAG-30 and reverse 50-CAGGCCACAGTTGCTCGG-30, P21: forward 50-
CATGTGGACCTGTCACTGTCTTGTA-30 and reverse 50-GAA-
GATCAGCCGGCGTTTG-30, and GAPDH: forward 50-AAGGCTGGGGCT-
CATTTGCA-30 and reverse 50-ATGACCTTGCCCACAGCCTT-3’.
2.6. Statistical analysis
The results are reported as means  SEM. The data were tested for
statistical significance using a one-way analysis of variance followed by a
Tukey's multiple comparison test using GraphPad Prism 5. For analysis
between two groups, Student's t-test was used. Differences were consid-
ered significant when P < 0.05.
3. Results
3.1. Differential changes of intracellular Ca2þ [Ca2þ]i levels in response to
sub-toxic and toxic levels of cisplatin in human breast cancer MCF-7 cells
To study whether cisplatin resistance in MCF-7 correlates with
intracellular Ca2þ concentration, we evaluated disturbances of intracel-
lular calcium with sub-toxic and toxic doses of cisplatin (CDDP). Cells
were treated with increasing doses of cisplatin (5 μM, 10 μM, 20 μM, 40
μM, and 100 μM) for 18 h and viability was determined by light micro-
scopy (Optika) (Figure 1A), and MTT assay (Figure 1B). Morphologically,
cells showed increase in the percentage of detachment, rounding, and
shrinkage starting at 40 μM,which was intensified at 100 μM (Figure 1A).
Figure 1. Differential changes of [Ca2þ]i levels in response to sub-toxic and toxic levels of cisplatin in human breast cancer MCF-7 cells. A. Light microscopy of MCF-7
cells untreated or treated with increasing doses of cisplatin, CDDP (5 μM, 10 μM, 20 μM, 40 μM, 100 μM) for 18 h. Cells were photographed with an inverted mi-
croscope (Optika) (scale, 100 μm). B. MTT analysis of MCF-7 cells treated as in A. After treatment, cell viability was determined using MTT-based in vitro toxicity
assay. Data are represented as a percentage of MTT activity where untreated cells were taken to be 100%. Experiments were repeated twice, each sample in triplicates.
Bar graphs represent mean  SEM. C. Cells were treated with cisplatin (20, 40, or 100 μM) for 18 h, and incubated with the fluorescent calcium indicator, Fluo-4 AM.
Calcium concentrations in the cytosol were observed by Optika XDS-2 inverted fluorescence microscope using FITC filter. D. Vertical scatter plots showing Fluo-4 AM
fluorescence intensity in individual cells treated with CDDP 20 μM (blue dots), CDDP 40 μM (orange dots), and CDDP 100 μM (red dots), or control cell (black dots).
Black line represent mean and whiskers are error bars. *P < 0.05; **P < 0.01; ***P < 0.001.
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logic changes showing signs of cell death, while at cisplatin (20 μM), cells
showed minimal signs of apoptosis (Figure 1A). MTT assay revealed a
significant reduction in cell viability following cisplatin 40 μM and 100
μM, consistent with morphological changes. Cisplatin at 20 μM showed a
slight decrease in cell viability but it did not reach statistical significance.
To evaluate [Ca2þ]i levels, we monitored intracellular Ca2þ using a
fluorescent Ca2þ indicator (Fluo-4 AM) in cells treated with sub-toxic (20
μM), 40 μM, and 100 μM cisplatin doses (Figure 1C). Fluorescence mi-
croscopy was used to observe alterations in free [Ca2þ]i levels. As shown
in Figure 1C, cisplatin treatment resulted in a dose-dependent increase in
Fluo-4 AM fluorescence intensity, suggesting an increase in [Ca2þ]i. Cell-
by-cell quantification of Fluo-4 signal showed that fluorescent intensity
was significantly increased with increasing doses of cisplatin (Figure 1D).
These results suggested a higher increase in [Ca]i in MCF-7 cells in
response to CDDP at toxic concentrations compared to sub-toxic dose.
3.2. Differential and dose-dependent regulation of gene expression of
calmodulin, S100A8, and S100A14 in MCF-7 cells treated with cisplatin
We examined the expression of calcium-binding proteins, calmodulin,
S100A8, and S100A14, in breast cancer cells in response to cisplatin
(Figure 2). These CaBPs, in particular, has been associated with cell
survival and apoptotic pathways in several breast cancer models [34, 35,3
36]. Cells treated with a sub-toxic dose (20 μM) of cisplatin showed
significant decrease by 46% of control levels in calmodulin mRNA levels
but no change in S100A14 mRNA levels. Conversely, S100A8 mRNA
levels were significantly increased to 273% of control levels at this dose.
At 40 μMdose, cisplatin resulted in significant decrease by approximately
60% in calmodulin and 29% of control levels in S100A14 mRNA levels
with a further decrease at 100 μM dose. To test whether the decrease in
the expression of three tested CaBPs mRNAs at toxic dose of CDDP
resulted from a global decrease in gene expression following cisplatin, we
studied in parallel the expression of p21, cyclin-dependent kinase in-
hibitor [37], known to be induced by cisplatin and contributes to the
maintenance of cell cycle arrest [38, 39, 40, 41]. Cisplatin treatment
induced a significant increase by 193%, 570%, and 450% of control
levels in p21 mRNA at cisplatin 20 μM, 40 μM, and 100 μM, respectively
(Figure 2, top left panel), suggesting that the decrease in CaBPs mRNAs
was not due to a global reduction in gene expression in cisplatin treated
cells.
3.3. Intracellular calcium chelator, BAPTA-AM, sensitizes MCF-7 to sub-
toxic dosage of cisplatin
We investigated the effect of BAPTA-AM, an intracellular Ca2þ
chelator, on cisplatin-induced cell death by light microscopy, MTT assay,
and nuclear morphology using DAPI staining (Figure 3). Morphologic
Figure 2. Differential and dose-dependent
effect of cisplatin on mRNA expression
levels of p21, calmodulin, S100A8, and
S100A14. After cells were exposed to sub-
toxic (20 μM), 40 μM, and 100 μM of
cisplatin for 18 h, mRNA expression levels
were quantified by qPCR. All mRNA
expression levels were normalized against
GAPDH. Statistically significant differ-
ences were determined by one-way
ANOVA. Statistical comparison between
two groups was performed using t-test.
Each value is the mean  SEM from three
independent experiments, each with three
replicates. *P <0.05, **P<0.01, ***P
<0.001.
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crease of cells showing typical apoptotic features such as rounding,
shrinkage, and detachment at 20 μM and 40 μM (Figure 3A). Quantifying
cell viability by MTT assay showed approximately 30% and 15%
decrease in viability of MCF-7 pre-treated with BAPTA-AM at 20 μM and
40 μM, respectively, compared to cisplatin alone (Figure 3B). However,
no significant changes were observed in cells treated with toxic-dose
(100 μM) in the presence of BAPTA-AM. Cells treated with BAPTA-AM
or cisplatin (20 μM), showed no significant change in cell viability per-
centage (Figure 3B). To further confirm the decrease in viability at 20 μM
and 40 μM doses, in the presence of BAPTA-AM, nuclear changes were
examined by DAPI staining. As shown in Figure 3C (arrows), morpho-
logical characteristics of apoptosis, including nuclear fragmentation,
nuclear condensation, and nuclear shrinkage, were apparent in cells
treated with cisplatin (40 μM). However, few changes were observed in
the cells treated with a sub-toxic dose of cisplatin (20 μM), BAPTA-AM, or
untreated group where cells had normal nuclear morphology (Figure 3C,
arrowheads). Cells treated with cisplatin (20 μM) in the presence of
BAPTA-AM showed increased signs of nuclear changes typical of
apoptotic cells, suggesting that BAPTA-AM enhances apoptosis and in-
creases the sensitivity of MCF-7 to a sub-toxic dose of cisplatin.3.4. Quantifying relative changes in intracellular calcium in the presence of
calcium chelator, BAPTA-AM
We monitored intracellular calcium alterations in the presence of
BAPTA-AM at single-cell level using Fluo-4 AM imaging (Figure 4A). In
cells treated with 20 μM cisplatin we detected a significant increase in4
Fluo-4 AM fluorescence compared to control cells (Figure 4A and B),
consistent with our previous results demonstrating increase in intracel-
lular calcium in a dose-dependent manner (Figure 1C and Figure 1D).
Cells treated with CDDP 20 μM in the presence of BAPTA-AM showed a
decrease in mean Fluo-4 signal compared to CDDP 20 μM alone. Inter-
estingly, cells treated with cisplatin (20 μM) in the presence of BAPTA-
AM exhibited distinct cell heterogeneity. We chose the cutoff value of
2 based on the maximum value obtained in the control sample. Inter-
estingly, 8.3% of cells (11 out of 131) treated with CDDP 20 μM in the
presence of BAPTA-AM exhibited a two-fold or higher increase in Fluo-4
AM signal, compared to 1.6% (2 out of 118 cells) in CDDP 20 μM as
shown in Figure 4B. This may be due to saturation of the BAPTA-AM
buffering capacity as previously reported [42,43]. Cells treated with
CDDP 40 μM showed a significant increase in mean intensity compared to
CDDP 20 μM. Similarly, in the presence of BAPTA-AM, cells treated with
CDDP 40 μM showed a decrease in mean Fluo-4 signal, as compared to
CDDP 40 μM alone. However, 5.2% (7 out of 134 cells) showed two-fold
or higher increase in Fluo-4 AM signal in CDDP 40 μM in the presence of
BAPTA, compared to 11.5% (15 out of 130 cells) in CDDP 40 μM alone.
These results suggest that moderate elevation of [Ca2þ]i contribute to
survival at sub-toxic dose of cisplatin.3.5. BAPTA-AM induced sensitization to sub-toxic-dose cisplatin is
associated with decrease in p21, calmodulin, S100A8, and S100A14
mRNA expression
We next evaluated the changes, in the presence of BAPTA-AM, on the
expression of p21, calmodulin, S100A8, and S100A14. As expected, sub-
Figure 3. Intracellular calcium chelator, BAPTA-AM, sensitizes breast cancer MCF-7 cells to sub-toxic dose of cisplatin. A. Light microscopy images of MCF-7 cells
from untreated (control), and those treated with BAPTA-AM (10 μM) for 30 min before exposure to 20 μM, 40 μM, or 100 μM cisplatin for 18 h. Scale bar: 100 μM. B.
Cell viability determined using MTT assay. Bars denote the percentage of cell viability mean  SEM from two independent experiments performed in triplicates. *P <
0.05, **P < 0.01, ***P<0.001. C. Representative fluorescent images of MCF-7 cells after DAPI staining. Cells were grown on glass-bottom plates before treated as in A.
Cells were then fixed with 4 % paraformaldehyde, and stained with DAPI. Apoptosis was studied with a fluorescence microscope with DAPI filter and 40X oil objective.
Scale bar: 20 μM. White arrows indicate apoptotic nuclei, and white arrowheads indicate normal nuclei.
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augmented at higher doses, 40 μM, and 100 μM (Figure 5A). In the
presence of BAPTA-AM, p21 mRNA levels were decreased by 44% when
compared with cisplatin (20 μM) alone. Similarly, the induction of p21 at
cisplatin (40 μM) and (100 μM) was significantly decreased in the pres-
ence of BAPTA-AM, suggesting that p21 expression is inversely associ-
ated with cell death in these conditions. Cells treated with BAPTA-AM
showed no effect on p21 mRNA, but significant increase in calmodulin,
S100A8, and S100A14 mRNA, compared to control cells, suggesting
possible compensation for greatly decreased cytosolic calcium. Calmod-
ulin mRNA levels decreased by 50% after cisplatin (20 μM) (Figure 5B)
where cells showed minimal cell death. In the presence of BAPTA-AM,
calmodulin mRNA showed further decrease up to 62% after cisplatin
(20 μM), and decrease to 86% after cisplatin (40 μM) and (100 μM)
(Figure 5B). Cells treated with sub-toxic (20 μM) cisplatin showed an
increase in S100A8 and this was reduced to 32% in the presence of
BAPTA-AM (Figure 5C). Similarly, S100A14 mRNA was significantly
decreased with BAPTA-AM as compared to cisplatin alone (Figure 5D).
S100A14 mRNA levels were similar in control and CDDP (20 μM) treated
samples. Cells treated with CDDP (40 μM) in the presence of BAPTA-AM
showed significant decrease in S100A8 mRNA but no change in S100A14
mRNA. No changes in S100A8 and S100A14mRNA levels in the presence
of BAPTA-AM at CDDP (100 μM) compared to CDDP (100 μM) alone.
Overall our results demonstrate that increased sensitivity to sub-toxic
cisplatin in the presence of BAPTA-AM is correlated with decrease mRNA
levels for p21 and calcium-binding proteins calmodulin, S100A8, and
S100A14. At higher CDDP doses (40 μM and 100 μM), BAPTA-AM has
differential effects on the expression of calmodulin, S100A8, and
S100A14.5
4. Discussion
Several studies demonstrated the interaction between cisplatin acti-
vated molecular pathways and calcium signaling in multiple types of
cancer, including breast cancer cells [44]. In cisplatin-sensitive and
resistant MCF-7 cells, real-time calcium imaging demonstrated reduced
increase in [Ca2þ]i in cisplatin-resistant MCF-7 cells compared to sensi-
tive cells, and that was associated with decreased cytotoxicity in
CDDP-resistant MCF-7 at lower CDDP doses [29]. However, the effect of
combination of calcium signaling modulators on the sensitivity of MCF-7
cells to sub-toxic and toxic doses of cisplatin, and potential changes in
expression of calcium-binding proteins (CaBPs) have not been explored.
Initially, we investigated the expression of CaBPs, calmodulin, S100A8,
and S100A14 inMCF-7 cells exposed to sub-toxic (20 μM) and toxic doses
(40 μM, 100 μM) of cisplatin. Several CaBPs were reported to be highly
expressed in several types of tumors, including S100A proteins in gastric
cancer [45], S100A8 and S100A9 in skin [46], and colorectal cancer
[47], and calmodulin, S100A8 and S100A14 in breast cancer 30, 31, 32,
33]. Calmodulin has been reported to be overexpressed in breast tumors
[48,49]. Calmodulin antagonists have been shown to overcome resis-
tance to TRAIL-based therapy in triple-negative breast cancer [50].
Several S100 proteins are differentially expressed in breast cancer tissue
compared with normal tissue [51], suggesting that these proteins may be
important in tumor development and progression [52,53]. High expres-
sion of S100A8 and S100A14 was associated with poor survival and
higher incidence in breast cancer patients [32,54]. In addition, increased
S100A8 expression enhanced the resistance of breast cancer cells to
chemotherapy by activating pro-survival pathways [55]. Here in our
study, we aimed to compare the expression of calmodulin, S100A8, and
Figure 4. A. Effects of BAPTA-AM on cisplatin-induced intracellular Ca2þ changes. Cells gown on glass-bottom dishes were either untreated (control) or treated with
BAPTA-AM (10 μM) for 30 min before exposure to 20 μM or 40 μM cisplatin. Some cells were exposed to 100 μM CDDP. After treatment, cells were washed HBSS (pH
7.2) and loaded with 5 μM Fluo-4 AM for 30 min in the dark at 37 C as described in under “Materials and Methods”. The intracellular fluorescence of Fluo-4 was
imaged using fluorescence microscopy with a green emission filter. BF, bright field. Scale bar: 20 μm. B. Fluo-4 fluorescence from individual cells was quantified and
shown as a Box plot with horizontal lines depicting medians and 10–90 percentile whiskers. Dashed red line represent cutoff of maximum value obtained in control
sample. (*P< 0.05, **P <0.01, ***P< 0.001, n ¼ 89–127 cells).
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we considered 20 μM of cisplatin as a sub-toxic dose as cells treated with
this dose showed slight decrease in cell viability but it did not reach
statistical significance. At sub-toxic CDDP (20 μM), we found differential
effects of cisplatin on calmodulin, S100A8, and S100A14 mRNA levels,
while these genes showed consistent decrease at CDDP (40 μM) and (100
μM) (Figure 2). The decrease in mRNA levels is unlikely due to a global
decrease in expression following cisplatin as the expression of p21, cell
cycle inhibitor, was increased in these conditions. The correlation be-
tween decrease of calmodulin, S100A8, and S100A14 mRNA levels
(Figure 5) and decreased viability (Figure 3), suggests that these CaBPs
may be an integral part of the survival mechanism against sub-toxic
cisplatin in MCF-7 cells.
Monitoring [Ca2þ]i demonstrated a significant increase in Fluo-4 AM
intensity in cells treated with sub-toxic CDDP, with a greater increase in
intensity at higher doses (Figures 1C and 1D). Similar results, while using
different doses and time-course of cisplatin, were reported by Al-Taweel
et al. [29]. We were interested to see the changes in the gene expression
profile of several CaBPs associated with breast cancer cells under6
sub-toxic dose of cisplatin that has been enhanced by calcium-dependent
modulation. We tested cisplatin toxicity in the presence of different
calcium signaling modulators (preliminary data) and selected
BAPTA-AM to correlate changes for CaBPs with sub-toxic (20 μM)
cisplatin.
The combined effect of cisplatin and calcium signaling modulators on
the viability of cancer cells has been tested in numerous studies. Shen et
al [56] reported that combining a toxic-dose of cisplatin with BAPTA-AM
markedly decreased the cell growth inhibition and rate of apoptosis in
Hela cells. This study also demonstrated that intracellular Ca2þ partici-
pated in ER stress-associated apoptosis induced by cisplatin. On the other
hand, Ma et al. [26] demonstrated that BAPTA-AM prevented the in-
crease in cytosolic Ca2þ and inhibited cisplatin-induced ROS generation
in ovarian cancer cells. This study suggested that the maintenance of
intracellular Ca2þ homeostasis protects cells from cisplatin-induced
apoptosis. Here we show that BAPTA-AM enhanced the sensitivity of
MCF-7 cells to sub-toxic dose of cisplatin suggesting the importance of
maintaining of low levels of [Ca2þ]i in the survival of these cells under
sub-toxic dose of the drug. Cell-by-cell analysis of Fluo-4 AM fluorescence
Figure 5. BAPTA-AM induced sensitization by sub-toxic-dose of cisplatin is associated with a decrease in mRNA expression of p21, calmodulin, S100A8, and
S100A14. A. Cells were exposed to sub-toxic (20 μM), 40 μM, and 100 μM of cisplatin for 18 h, in the presence or absence of BAPTA-AM. After treatment, total RNA
was extracted from cells followed by cDNA synthesis and real-time qPCR. All mRNA expression levels were normalized against GAPDH. The data show the normalized
expression of (A) p21, (B) calmodulin, (C) S100A8, and (D) S100A14, relative to the expression of the control. Each value is the mean  SEM. Experiments were
conducted with triplicate samples and repeated at least twice. Statistically significant differences were determined by one-way ANOVA. Statistical comparison between
two groups was performed using t-test, *P <0.05, **P <0.01, ***P <0.001.
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BAPTA-AM, at sub-toxic (20 μM) and toxic dose (40 μM) of cisplatin. This
might suggest that BAPTA-AM is enhancing cisplatin cytotoxicity by
disrupting [Ca2þ]i homeostasis necessary for survival. The profound
effect of BAPTA-AM with sub-toxic cisplatin compared to a higher dose
might be explained by studies showing dose-dependent rise in [Ca2þ]i
associated with apoptotic death by CDDP [57]. This is partially supported
by analyzing cells showing high Fluo-4 fluorescence (higher than the
cutoff value used) in 11.5% of cells treated with CDDP 40 μM compared
to 1.6% with sub-toxic CDDP (Figure 4). This might explain the weak
effect of BAPTA-AM with CDDP 40 μM where increase in [Ca2þ]i could
be a stressor signal compared to survival signal with sub-toxic cisplatin.
Although this remains a speculation at this point, previous studies have
shown activation of survival pathways promoting autophagy at low dose
cisplatin [58].
On the other hand, S100 proteins have been shown to be closely
associated with calcium-mediated signalling, similar to IP3R1 which7
plays a critical role in the calcium-associated apoptotic pathway [8,17,
18]
Calcium-binding proteins, including calmodulin and S100 proteins,
have been shown to be an integral component of cellular events
controlled by Ca2þ [59]. Calmodulin has been shown to play crucial roles
in cell cycle progression through G1 and mitosis [60,61]. Several
chemical inhibitors of calmodulin have been used to inhibit several types
of tumors [62]. In human ovarian cells, combination of calmodulin
antagonist and cisplatin potentiated the effect of cisplatin in these cells
[63]. Using a comparative analysis of expression, we show a significant
decrease in calmodulin mRNA levels by ~46%, 60%, and 80% in cells
treated with sub-toxic CDDP (20 μM), 40 μM, and 100 μM, respectively.
The enhanced sensitivity of MCF-7 cells treated with sub-toxic CDDP
combined with BAPTA-AM is associated with a further decrease by 30%
in calmodulin expression, suggesting a negative correlation between
calmodulin expression and cisplatin sensitivity in MCF-7 cells. To test
whether cisplatin treatment is causing a global reduction of gene
expression, we studied the expression of p21 which is known to be
R. Hodeify et al. Heliyon 7 (2021) e06041induced by cisplatin. As expected, p21 levels in cells treated with
sub-toxic CDDP was elevated although to a lesser degree compared to
CDDP higher doses. In the presence of BAPTA-AM, the observed increase
in p21 at CDDP 20 μMwas significantly blunted and tended to reverse as
the concentration of cisplatin was increased (Figure 5), suggesting that
increase in p21 is modulated by intracellular [Ca2þ]i. These results
support studies demonstrating enhanced apoptosis rate to cisplatin in
p21 knockdown ovarian and testicular cancer cells [64,65], and kidney
cells [40]. Similarly, we found negative correlation between S100A14
expression and cisplatin sensitivity in cells treated with sub-toxic CDDP
in the presence of BAPTA-AM, while no significant change in CDDP
alone. Xu et al [25] reported that siRNA-mediated silencing of S100A14
in MCF-7 cells caused inhibition of HER-mediated proliferation. Our re-
sults suggest a positive role for calmodulin, S100A8, and S100A14 in the
survival of MCF-7 cells at sub-toxic levels of cisplatin. S100A8 mRNA
levels increased after cisplatin treatment at sub-toxic levels (Figures 2C
and 5C), consisting with the previous reports associating increased
S100A8 expression with the poor prognosis in breast cancer [66]. Cells
treated with cisplatin in the presence of BAPTA-AM had significantly
blunted the induction of S100A8 mRNA levels as compared to cisplatin
alone. In the presence of BAPTA-AM, CDDP 40 μM caused significant
decrease by 70% in S100A8 mRNA levels, while no significant change in
S100A8 expression was observed at CDDP 100 μM, suggesting a differ-
ential dose-dependent regulation of S100A8 by cisplatin, in the presence
of BAPTA-AM. Our findings are consistent with studies showing that
knockdown of S100A8 decreased proliferation in thyroid carcinoma cells
[67] and enhanced arsenic trioxide-induced apoptosis in leukemia cells
[68].
5. Conclusions
In conclusion, our data demonstrated decrease in mRNA levels in
calcium-binding proteins, calmodulin, S100A8, S100A14 at toxic doses
of cisplatin (40 μM and 100 μM). At sub-toxic CDDP (20 μM) levels, we
found differential gene expression changes in calmodulin and S100A8
while no significant change in S100A14 mRNA levels at this dose. We
also demonstrated that the sensitivity of sub-toxic cisplatin is enhanced
by intracellular calcium chelator, BAPTA-AM. Furthermore, BAPTA-AM
prevented the increase in intracellular calcium induced by cisplatin.
Enhancing sub-toxic cisplatin sensitivity by BAPTA-AM is accompanied
by decrease in calmodulin, S100A8, and S100A14, compared to sub-toxic
dose alone. We propose that modulating the activity of CaBPs plays a role
in sensitivity of MCF-7 cells to sub-toxic cisplatin doses. Future studies
investigating the biological function of calmodulin, S100A8, and
S100A14 in breast cancer should verify the possibility that these proteins
are targets to enhance CDDP-based chemotherapy.
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